UCLA researchers have described cost across an entire care process for benign prostate hyperplasia (BPH) using a novel strategy developed by Harvard Business School healthcare economists called time-driven activity-based costing.

They found a 400 percent discrepancy between the least and most expensive ways to treat the condition. The finding takes on even further importance as there isn’t any proven difference in outcomes between the lower and higher cost treatments, said study first author Alan Kaplan, M.D., a resident physician in the UCLA urology department.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access